Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

84.3K
Overview
84.3K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

7.6K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.6K
What is the Immune System?01:38

What is the Immune System?

132.4K
Overview
132.4K
Humoral Immune Responses01:36

Humoral Immune Responses

84.1K
Overview
84.1K
Receptor-mediated Endocytosis01:38

Receptor-mediated Endocytosis

111.4K
Overview
111.4K
Nonsense-mediated mRNA Decay02:27

Nonsense-mediated mRNA Decay

11.9K
The Upf proteins that carry out nonsense-mediated decay (NMD) are found in all eukaryotic organisms, including humans. Each protein has an individual role, but they need to work in collaboration. Upf1 is an ATP-dependent RNA helicase that unwinds the RNA helix. Because Upf1 can unwind any RNA, Upf2 and Upf3 are required to help Upf1 discriminate between nonsense and normal mRNAs.
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
11.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychiatric comorbidities cluster early after onset in MOGAD: a cross-sectional comparative study with MS and NMOSD.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Cerebellar Involvement in Attacks of Aquaporin-4-IgG Positive Neuromyelitis Optica Spectrum Disorder.

Neurology(R) neuroimmunology & neuroinflammation·2024
Same author

Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.

The Lancet. Neurology·2024
Same author

MRI of the relevant domain should be performed to confirm whether clinical symptoms represent an attack of NMOSD: Yes.

Multiple sclerosis (Houndmills, Basingstoke, England)·2024
Same author

Alterations in Aquaporin-4-IgG Serostatus in 986 Patients: A Laboratory-Based Longitudinal Analysis.

Annals of neurology·2023
Same author

Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum.

Multiple sclerosis (Houndmills, Basingstoke, England)·2023
Same journal

Key Considerations in Telestroke Program Management.

Continuum (Minneapolis, Minn.)·2026
Same journal

Neurology's Action Potential: Delivering on the Promise of Brain Health.

Continuum (Minneapolis, Minn.)·2026
Same journal

Erratum.

Continuum (Minneapolis, Minn.)·2026
Same journal

Management of Large Artery Atherosclerosis.

Continuum (Minneapolis, Minn.)·2026
Same journal

Thrombolysis, Thrombectomy, and Antithrombotic Therapy for Acute Ischemic Stroke.

Continuum (Minneapolis, Minn.)·2026
Same journal

Stroke in Children and Younger Adults.

Continuum (Minneapolis, Minn.)·2026
See all related articles

Related Experiment Video

Updated: Feb 12, 2026

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
05:31

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Published on: August 7, 2017

11.0K

Immune-Mediated Myelopathies.

Dean M Wingerchuk

    Continuum (Minneapolis, Minn.)
    |April 4, 2018
    PubMed
    Summary
    This summary is machine-generated.

    Autoimmune myelopathies are diagnosed using clinical data, MRI, and autoantibody markers. Early diagnosis and treatment are crucial for managing these inflammatory spinal cord disorders and preventing relapse.

    More Related Videos

    Characterization of Immune Cells and Proinflammatory Mediators in the Pulmonary Environment
    09:00

    Characterization of Immune Cells and Proinflammatory Mediators in the Pulmonary Environment

    Published on: June 24, 2020

    3.8K
    In Vitro Analysis of Myd88-mediated Cellular Immune Response to West Nile Virus Mutant Strain Infection
    10:39

    In Vitro Analysis of Myd88-mediated Cellular Immune Response to West Nile Virus Mutant Strain Infection

    Published on: November 27, 2014

    8.5K

    Related Experiment Videos

    Last Updated: Feb 12, 2026

    Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
    05:31

    Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

    Published on: August 7, 2017

    11.0K
    Characterization of Immune Cells and Proinflammatory Mediators in the Pulmonary Environment
    09:00

    Characterization of Immune Cells and Proinflammatory Mediators in the Pulmonary Environment

    Published on: June 24, 2020

    3.8K
    In Vitro Analysis of Myd88-mediated Cellular Immune Response to West Nile Virus Mutant Strain Infection
    10:39

    In Vitro Analysis of Myd88-mediated Cellular Immune Response to West Nile Virus Mutant Strain Infection

    Published on: November 27, 2014

    8.5K

    Area of Science:

    • Neurology
    • Immunology
    • Neuroscience

    Background:

    • Immune-mediated myelopathies present with acute or subacute symptoms.
    • A broad differential diagnosis is common in these conditions.
    • Recent advances in identifying neural autoantibodies have transformed diagnosis and treatment.

    Purpose of the Study:

    • To review the clinical presentation, diagnostic evaluation, and management of immune-mediated myelopathies.
    • To highlight the role of autoantibodies and MRI in diagnosis.
    • To discuss the impact of accurate diagnosis on treatment and prognosis.

    Main Methods:

    • Review of clinical presentation and diagnostic approaches.
    • Analysis of MRI findings in spinal cord and brain.
    • Evaluation of autoantibody detection and cerebrospinal fluid (CSF) data.

    Main Results:

    • Neural autoantibodies and their targets aid in diagnosing autoimmune myelopathies and identifying paraneoplastic syndromes.
    • Distinctive MRI lesion patterns help differentiate inflammatory myelopathies.
    • A systematic diagnostic approach improves disease classification and prognostic accuracy.

    Conclusions:

    • Accurate diagnosis of immune-mediated myelopathies is essential for effective treatment.
    • Early immunotherapy can arrest and reverse neurologic injury.
    • Prognostic information guides long-term management to prevent progression or relapse.